Prosecution Insights
Last updated: July 17, 2026
Application No. 18/731,597

SURGICAL PAD REINFORCEMENT

Final Rejection §102
Filed
Jun 03, 2024
Priority
Dec 03, 2021 — provisional 63/264,919 +1 more
Examiner
DAVID, SHAUN L
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Edwards Lifesciences Corporation
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
1y 5m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
418 granted / 573 resolved
+2.9% vs TC avg
Strong +19% interview lift
Without
With
+19.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
27 currently pending
Career history
621
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
63.7%
+23.7% vs TC avg
§102
17.6%
-22.4% vs TC avg
§112
4.9%
-35.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 573 resolved cases

Office Action

§102
DETAILED ACTION This Office Action is a Response to Applicant’s Arguments and Amendment submitted 02/002/2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Newly submitted claims 24-26 and 27-29 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: Restriction to one of the following inventions is required under 35 U.S.C. 121: I. Claims 1-6, 9, 11, 13-14, 16, and 21-23, drawn to a reinforced surgical pad device, classified in a61b2017/0406. II. Claims 24-26 and 27-29, drawn to a cardiac tissue anchoring system and a medical implant for anchoring to a tissue wall of a heart, classified in a61f2/2442. The inventions are independent or distinct, each from the other because: Inventions I and II are directed to related products. The related inventions are distinct if: (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed have a materially different mode of operation, function or effect, in that invention II is designed specifically for use in anchoring cardiac tissue on a surface of the heart, whereas invention I is a generic reinforced surgical pad device that is capable of being applied to any tissue anywhere in the body for reinforcing a mesh, such as occluding an opening or sealing a hole or wound. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants. Restriction for examination purposes as indicated is proper because all the inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and/or examination burden if restriction were not required because one or more of the following reasons apply: The inventions have acquired a separate status in the art in view of their different classification; The inventions have acquired a separate status in the art due to their recognized divergent subject matter; and/or The inventions require a different field of search (e.g., searching different classes /subclasses or electronic resources, or employing different search strategies or search queries). Applicant is advised that the reply to this requirement to be complete must include (i) an election of an invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention. The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 24-26 and 27-29 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. To preserve a right to petition, the reply to this action must distinctly and specifically point out supposed errors in the restriction requirement. Otherwise, the election shall be treated as a final election without traverse. Traversal must be timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are subsequently added, applicant must indicate which of the subsequently added claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 and 23 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 2013/0060263 A1 to Bailly et al. (hereinafter “Bailly”) (previously made of record by the Examiner). Regarding claim 1, Bailly discloses (see abstract; Figs. 3-15; and [0056]-[0107]) a reinforced surgical pad device (300), comprising: a surgical pad (1) configured to be positioned over an opening in a target tissue; and a reinforcement member (200) coupled to the surgical pad, the reinforcement member comprising: a central portion (201a and 205) coupled to the surgical pad, and a circumferential portion (201b) disposed around the central portion, at least a portion of the circumferential portion being sized to extend laterally beyond an outer edge of the surgical pad (see [0100]), wherein the surgical pad and the reinforcement member are configured to be disposed parallel to each other when deployed at the opening in the target tissue (see Figs. 6/15). Regarding claim 23, Bailly discloses wherein the surgical pad comprises a flexible material (see Fig. 5 and [0059]) capable of having one or more tethers (303) pass through and anchor to the surgical pad (see Figs. 13-15 and [0096]). Allowable Subject Matter Claims 2-3, 4-6, 9, 11, 13-14, and 21-22 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: with respect to claims 2 and 3, neither Bailly nor any other prior art of record teaches a central portion of the reinforcement member comprises a recess or an opening sized to fit the surgical pad inset into the recess or sized to fit into the opening. While Bailly teaches a central portion (i.e., defined by element 205 in Figs. 3/7), the surgical pad is never inset into or sized to fit within the central portion – rather it is adjoining the reinforcement member and its central portion. It is also noted that the EPO indicated similar language as being allowable in the corresponding European application. Response to Arguments Applicant’s arguments with respect to the claims have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAUN L DAVID whose telephone number is (571)270-5263. The examiner can normally be reached M-F 10AM-6:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 571-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHAUN L DAVID/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Jun 03, 2024
Application Filed
Nov 04, 2025
Non-Final Rejection mailed — §102
Jan 21, 2026
Applicant Interview (Telephonic)
Jan 21, 2026
Examiner Interview Summary
Feb 02, 2026
Response Filed
May 11, 2026
Examiner Interview (Telephonic)
May 22, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12667369
MEDICAL DEVICE AND TREATMENT METHOD
1y 11m to grant Granted Jun 30, 2026
Patent 12661220
Platforms For Mitral Valve Replacement
4y 0m to grant Granted Jun 23, 2026
Patent 12661225
DEVICES, SYSTEMS, AND METHODS FOR ADJUSTING THE POSITION OF AN IMPLANTABLE ELEMENT
3y 9m to grant Granted Jun 23, 2026
Patent 12661122
APPARATUS AND METHODS FOR OCCLUDING AN ANATOMICAL STRUCTURE
2y 12m to grant Granted Jun 23, 2026
Patent 12661148
INSERTING MEMBER LEAD-OUT DEVICE
1y 10m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
92%
With Interview (+19.2%)
3y 7m (~1y 5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 573 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month